IP Library › Granted Patent US 12,630,630
Granted Patent B2
US 12,630,630 · App. 18/189,998 · Granted May 19, 2026

Anti-CD47 antibodies and methods of use

Inventors: Jiin-Tarng Wang (Shanghai, CN); Chi-Ling Tseng (Shanghai, CN); Wei-Dong Jiang (Shanghai, CN)
Assignees: Shanghai Henlius Biotech, Inc.; Shanghai Henlius Biopharmaceutical Co., Ltd.; Shanghai Henlius Biologics Co., Ltd.
C07K16/2803A61P35/00C07K14/7051C12N15/63A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,630,630
App. No.
18/189,998
Granted
May 19, 2026
Kind
B2
Abstract

The present disclosure relates to antibodies and antibody derivatives that bind to CD47 (also known as IAP, MER6 and OA3) and methods of using the same. In certain embodiments, an anti-CD47 antibody or antibody derivative disclosed herein exhibits reduced binding to a red blood cell.

Claims (35)

1 . An antibody that binds to CD47 comprising:

a) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 1, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 3; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 4, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 6;

b) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 11, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 13; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 14, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 16;

c) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 21, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 22, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 23; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 24, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 25, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 26;

d) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 31, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 32, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 33; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 34, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 36;

e) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 41, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 43; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 44, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 45, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 46;

f) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 51, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 52, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 53; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 54, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 56; or

g) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 61, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 62, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 63; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 64, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 65, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 66.

2 . The antibody of claim 1 , wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 61, (2) a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 62, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 63; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 64, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 65, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 66.

3 . The antibody of claim 1 , wherein the antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8;

b) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 18;

c) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 27, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 28;

d) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 38;

e) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 47, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 48;

f) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 57, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 58; or

g) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 67, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 68.

4 . The antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 67, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 68.

5 . The antibody of claim 1 , wherein the antibody comprises a full-length immunoglobulin, a single-chain Fv (scFv) fragment, a Fab fragment, a Fab′ fragment, a F(ab′)2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a Fv-Fc fusion, a scFv-Fc fusion, a scFv-Fv fusion, a diabody, a tribody, a tetrabody or any combination thereof.

6 . The antibody of claim 1 , wherein the antibody comprises a Fc region.

7 . The antibody of claim 6 , wherein the Fc region comprises a Fc region selected from the group consisting of the Fc regions of IgG1, IgG2, IgG3 and IgG4.

8 . The antibody of claim 7 , wherein the Fc region comprises an IgG1 Fc region.

9 . The antibody of claim 7 , wherein the Fc region comprises an IgG4 Fc region.

10 . The antibody of claim 7 , wherein the Fc region comprises a C-terminal lysine.

11 . The antibody of claim 7 , wherein the Fc region comprises a deletion of a C-terminal lysine.

12 . An immunoconjugate comprising the antibody of claim 1 , linked to a therapeutic agent or a label.

13 . A chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain that comprises an antibody of claim 1 .

14 . An immunoresponsive cell comprising a CAR of claim 13 .

15 . A pharmaceutical composition comprising a) the antibody of claim 1 , and b) a pharmaceutically acceptable carrier.

16 . A nucleic acid encoding the antibody of claim 1 .

17 . A vector comprising the nucleic acid of claim 16 .

18 . A host cell comprising the nucleic acid of claim 16 .

19 . A method for preparing an antibody of claim 1 , comprising expressing the antibody in a host cell comprising a nucleic acid encoding the antibody and isolating the antibody from the host cell.

20 . A method of reducing tumor burden in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 15 .

21 . A kit comprising an antibody of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2026
From: WANG, JIIN-TARNG; TSENG, CHI-LING; JIANG, WEI-DONG
To: SHANGHAI HENLIUS BIOTECH, INC.
Reel/Frame 074132/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2026
From: SHANGHAI HENLIUS BIOTECH, INC.
To: SHANGHAI HENLIUS BIOLOGICS CO., LTD.
Reel/Frame 074090/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2026
From: SHANGHAI HENLIUS BIOTECH, INC.
To: SHANGHAI HENLIUS BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 074089/0975 →
Priority Claims (1)
WO PCT/CN2020/118320 · Sep 28, 2020 · international
Continuity (2)
Continuation PCTCN2021121314 · Sep 28, 2021
Related Publication 20230279110A1 · Sep 7, 2023
References Cited (14)
US 20190023784A1 · Chalons-Cottavoz et al. · 2019 [cited by applicant]
US 20200048369A1 · Liu et al. · 2020 [cited by applicant]
US 20200270345A1 · Solovyev et al. · 2020 [cited by applicant]
CN 106117354A · 2016 [cited by applicant]
CN 111087470A · 2020 [cited by applicant]
JP 2019508030A · 2019 [cited by applicant]
RU 2693078C2 · 2017 [cited by applicant]
WO 2017196793A1 · 2017 [cited by applicant]
WO 2019144895A1 · 2019 [cited by applicant]
European Patent Office Form 1707 Supplementary Partial European Search Report under Rule 164, paragraph 1 of the European Patent Convention Sep. 24, 2024 14 pp. CH. [cited by applicant]
Jingping Yuan et al., High expression of CD47 in triple negative breast cancer is associated with epithelial mesenchymal transition and poor prognosis, Oncology Letters, 2019, 18: 3249-3255. [cited by applicant]
Xiaojuan Liu et al., Is CD47 an innate immune checkpoint for tumor evasion?, Journal of Hematology & Oncology, 2017, 10:12, (2 pages) abstract. [cited by applicant]
Office Action from the JPO issued on Sep. 2, 2025. [cited by applicant]
HemaSphere vol. 4, Suppl 1019-1020. Jun. 12, 2020vol. 4, Suppl. 1, 2020 PB2273 a Preclinical Study of IMC-<l02, A Fully Human Therapeutic Antibody Safely Targeting CD47 in Cancer pp. 1019-1020. [cited by applicant]